Advances in bladder cancer imaging

BMC Medicine

Robert Huddart¹  Shaista Hafeez¹ 

[1] The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Sutton, Surrey, UK

关键词: Virtual cystoscopy;    Ultrasound;    Staging;    PET-CT;    Multidetector computed tomography;    Diffusion-weighted MRI;    Bladder cancer;   

Others  :  857095
DOI  :  10.1186/1741-7015-11-104

 received in 2012-12-21, accepted in 2013-03-14,  发布年份 2013

【 摘 要 】

The purpose of this article is to review the imaging techniques that have changed and are anticipated to change bladder cancer evaluation. The use of multidetector 64-slice computed tomography (CT) and magnetic resonance imaging (MRI) remain standard staging modalities. The development of functional imaging such as dynamic contrast-enhanced MRI, diffusion-weighted MRI and positron emission tomography (PET)-CT allows characterization of tumor physiology and potential genotypic activity, to help stratify and inform future patient management. They open up the possibility of tumor mapping and individualized treatment solutions, permitting early identification of response and allowing timely change in treatment. Further validation of these methods is required however, and at present they are used in conjunction with, rather than as an alternative to, conventional imaging techniques.

【 授权许可】

   
2013 Hafeez and Huddart; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]UK Office for National Statistics: Mortality statistics EaW. [http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-incidence-and-mortality/2008-2010/index.html webcite]
• [2]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [3]Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: (Eds): AJCC Cancer Staging Maual. 7th edition. New York, NY: Springer; 2010.
• [4]Jewett HJ, Strong GH: Infiltrating carcinoma of the bladder; relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J Urol 1946, 55:366-372.
• [5]MacVicar AD: Bladder cancer staging. BJU Int 2000, 86(Suppl 1):111-122.
• [6]Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
• [7]Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS: Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001, 166:490-493.
• [8]Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W: Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 2005, 95:786-790.
• [9]Mehrsai A, Mansoori D, Taheri Mahmoudi M, Sina A, Seraji A, Pourmand GH: A comparison between clinical and pathologic staging in patients with bladder cancer. Urol J 2004, 1:85-89.
• [10]Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B: The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003, 43:241-245.
• [11]Martingano P, Stacul F, Cavallaro M, Casagrande F, Cernic S, Belgrano M, Cova M: 64-Slice CT urography: 30 months of clinical experience. Radiol Med 2010, 115:920-935.
• [12]Wang LJ, Wong YC, Ng KF, Chuang CK, Lee SY, Wan YL: Tumor characteristics of urothelial carcinoma on multidetector computerized tomography urography. J Urol 2010, 183:2154-2160.
• [13]Kundra V, Silverman PM: Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol 2003, 180:1045-1054.
• [14]Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI: Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 2000, 163:1693-1696.
• [15]Tritschler S, Mosler C, Tilki D, Buchner A, Stief C, Graser A: Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. Urology 2012, 79:1317-1321.
• [16]Abu-Yousef MM, Narayana AS, Franken EA Jr, Brown RC: Urinary bladder tumors studied by cystosonography. Part I: Detection. Radiology 1984, 153:223-226.
• [17]Abu-Yousef MM, Narayana AS, Brown RC, Franken EA Jr: Urinary bladder tumors studied by cystosonography. Part II: Staging. Radiology 1984, 153:227-231.
• [18]Nicolau C, Bunesch L, Peri L, Salvador R, Corral JM, Mallofre C, Sebastia C: Accuracy of contrast-enhanced ultrasound in the detection of bladder cancer. Br J Radiol 2011, 84:1091-1099.
• [19]Caruso G, Salvaggio G, Campisi A, Melloni D, Midiri M, Bertolotto M, Lagalla R: Bladder tumor staging: comparison of contrast-enhanced and gray-scale ultrasound. AJR Am J Roentgenol 2010, 194:151-156.
• [20]Park HJ, Hong SS, Kim JH, Kwon SB, Kwon KH, Choi DL, Park ST, Chang YW, Hwang JH: Tumor detection and serosal invasion of bladder cancer: role of three-dimensional volumetric reconstructed US. Abdom Imaging 2010, 35:265-270.
• [21]Li QY, Tang J, He EH, Li YM, Zhou Y, Zhang X, Chen G: Clinical utility of three-dimensional contrast-enhanced ultrasound in the differentiation between noninvasive and invasive neoplasms of urinary bladder. Eur J Radiol 2012, 81:2936-2942.
• [22]Xu HX, Lu MD, Xie XH, Xie XY, Kuang M, Xu ZF, Liu GJ, Wang Z, Chen LD, Lin MX: Treatment response evaluation with three-dimensional contrast-enhanced ultrasound for liver cancer after local therapies. Eur J Radiol 2010, 76:81-88.
• [23]Gollub MJ, Gultekin DH, Akin O, Do RK, Fuqua JL 3rd, Gonen M, Kuk D, Weiser M, Saltz L, Schrag D, Goodman K, Paty P, Guillem J, Nash GM, Temple L, Shia J, Schwartz LH: Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. Eur Radiol 2012, 22:821-831.
• [24]Saksena MA, Dahl DM, Harisinghani MG: New imaging modalities in bladder cancer. World J Urol 2006, 24:473-480.
• [25]Tekes A, Kamel I, Imam K, Szarf G, Schoenberg M, Nasir K, Thompson R, Bluemke D: Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol 2005, 184:121-127.
• [26]Thomsen HS: Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 2009, 47:827-831.
• [27]Padhani AR, Husband JE: Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001, 56:607-620.
• [28]Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, D'Arcy JA, Collins DJ, Pittam MR, Ravichandran D, Padhani AR: Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008, 14:6580-6589.
• [29]Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA, Stirling JJ, Saunders MI, Hoskin PJ, Phillips H, Padhani AR, Griffiths JR: BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 2001, 14:156-163.
• [30]Afaq A, Koh DM, Padhani A, van As N, Sohaib SA: Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU Int 2011, 108:1716-1722.
• [31]Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
• [32]Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S: Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2010, 31:60-66.
• [33]Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J: Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009, 252:182-189.
• [34]Kyriazi S, Collins DJ, Messiou C, Pennert K, Davidson RL, Giles SL, Kaye SB, Desouza NM: Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging–value of histogram analysis of apparent diffusion coefficients. Radiology 2011, 261:182-192.
• [35]El-Assmy A, Abou-El-Ghar ME, Mosbah A, El-Nahas AR, Refaie HF, Hekal IA, El-Diasty T, Ibrahiem el H: Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol 2009, 19:1575-1581.
• [36]Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, Suzuki K, Oshima H, Hara M, Shibamoto Y: Urinary bladder cancer: diffusion-weighted MR imaging–accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009, 251:112-121.
• [37]Chen CY, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, Hsu JS, Liu GC: Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants–initial experience. Radiology 2006, 239:448-456.
• [38]Cui Y, Zhang XP, Sun YS, Tang L, Shen L: Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008, 248:894-900.
• [39]Harry VN, Semple SI, Gilbert FJ, Parkin DE: Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008, 111:213-220.
• [40]Yoshida S, Koga F, Kobayashi S, Ishii C, Tanaka H, Tanaka H, Komai Y, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K: Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012, 83:e21-7.
• [41]Papalia R, Simone G, Grasso R, Augelli R, Faiella E, Guaglianone S, Cazzato R, Del Vescovo R, Ferriero M, Zobel B, Gallucci M: Diffusion-weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases. BJU Int 2012, 109:1031-1036.
• [42]Harisinghani MG, Saini S, Hahn PF, Weissleder R, Mueller PR: MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (Combidex). Acad Radiol 1998, 5(Suppl 1):S167-S169.
• [43]Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, Fleischmann A, Vermathen P, Studer UE: Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009, 55:761-769.
• [44]Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, van de Kaa CA H, Kaufmann D, Barentsz JO: Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004, 233:449-456.
• [45]Beer A, Saar B, Rummeny EJ: Tumors of the urinary bladder: technique, current use, and perspectives of MR and CT cystography. Abdom Imaging 2003, 28:868-876.
• [46]Bernhardt TM, Schmidl H, Philipp C, Allhoff EP, Rapp-Bernhardt U: Diagnostic potential of virtual cystoscopy of the bladder: MRI vs CT. Preliminary report. Eur Radiol 2003, 13:305-312.
• [47]Tsili A, Tsampoulas C, Chatziparaskevas N, Silakos A, Kalef-Ezra J, Sofikitis N, Efremidis SC: Computed tomographic virtual cystoscopy for the detection of urinary bladder neoplasms. Eur Urol 2004, 46:579-585.
• [48]Lalondrelle S, Sohaib SA, Castellano IA, Mears D, Huddart R, Khoo V: Investigating the relationship between virtual cystoscopy image quality and CT slice thickness. Br J Radiol 2012, 85:1112-1117.
• [49]Qu X, Huang X, Wu L, Huang G, Ping X, Yan W: Comparison of virtual cystoscopy and ultrasonography for bladder cancer detection: a meta-analysis. Eur J Radiol 2011, 80:188-197.
• [50]Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, Bockisch A, Debatin JF, Freudenberg LS: Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004, 22:4357-4368.
• [51]Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, Gorges R, Nowrousian MR, Bockisch A, Debatin JF: FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004, 31:325-329.
• [52]Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003, 348:2500-2507.
• [53]Schoder H, Larson SM, Yeung HW: PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004, 45(Suppl 1):72S-81S.
• [54]Ahlstrom H, Malmstrom PU, Letocha H, Andersson J, Langstrom B, Nilsson S: Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996, 37:180-185.
• [55]Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE: 18 F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007, 48:764-770.
• [56]Harkirat S, Anand S, Jacob M: Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers. Indian J Radiol Imaging 2010, 20:13-19.
• [57]Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL: Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997, 24:615-620.
• [58]Vesselle HJ, Miraldi FD: FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics 1998, 18:805-823.
• [59]Liu IJ, Lai YH, Espiritu JI, Segall GM, Srinivas S, Nino-Murcia M, Terris MK: Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int 2006, 77:69-75.
• [60]Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY, Kao CH: Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 2012, 81:2411-2416.
• [61]Bouchelouche K, Oehr P: Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 2008, 179:34-45.
• [62]Oyen WJ, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, Brans B: Targeted therapy in nuclear medicine–current status and future prospects. Ann Oncol 2007, 18:1782-1792.
• [63]de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W: Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging 2002, 29:1283-1288.
• [64]Gofrit ON, Mishani E, Orevi M, Klein M, Freedman N, Pode D, Shapiro A, Katz R, Libson E, Chisin R: Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 2006, 176:940-944.
• [65]Picchio M, Treiber U, Beer AJ, Metz S, Bössner P, van Randenborgh H, Paul R, Weirich G, Souvatzoglou M, Hartung R, Schwaiger M, Piert M: Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006, 47:938-944.
• [66]Jana S, Blaufox MD: Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006, 36:51-72.
• [67]DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, Coleman RE: Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001, 42:1805-1814.
• [68]Kruger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, Wibmer T, Merk T, Hombach V, Reske SN: Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18 F-fluoride PET or 18 F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009, 36:1807-1812.
• [69]Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I: The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18 F-fluoride PET, and 18 F-fluoride PET/CT. J Nucl Med 2006, 47:287-297.
• [70]Bouchelouche K, Capala J: ‘Image and treat’: an individualized approach to urological tumors. Curr Opin Oncol 2010, 22:274-280.
• [71]Zoller F, Eisenhut M, Haberkorn U, Mier W: Endoradiotherapy in cancer treatment–basic concepts and future trends. Euro J Pharmacol 2009, 625:55-62.
• [72]Rajjayabun PH, Keegan PE, Lunec J, Mellon JK: erbB receptor expression patterns in human bladder cancer. Urology 2005, 66:196-200.
• [73]Rotterud R, Nesland JM, Berner A, Fossa SD: Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005, 95:1344-1350.
• [74]Kramer-Marek G, Kiesewetter DO, Capala J: Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med 2009, 50:1131-1139.
• [75]Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J: [18 F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008, 35:1008-1018.
• [76]Orlova A, Tran TA, Ekblad T, Karlstrom AE, Tolmachev V: (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2010, 37:260-269.
• [77]Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY: Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007, 67:2773-2782.
• [78]Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, Thielscher A, Kneilling M, Lichy MP, Eichner M, Klingel K, Reischl G, Widmaier S, Röcken M, Nutt RE, Machulla HJ, Uludag K, Cherry SR, Claussen CD, Pichler BJ: Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 2008, 14:459-465.
• [79]Pichler BJ, Kolb A, Nagele T, Schlemmer HP: PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010, 51:333-336.
• [80]Delso G, Ziegler S: PET/MRI system design. Eur J Nucl Med Mol Imaging 2009, 36(Suppl 1):S86-S92.
• [81]Rioja J, Rodriguez-Fraile M, Lima-Favaretto R, Rincon-Mayans A, Penuelas-Sanchez I, Zudaire-Bergera JJ, Parra RO: Role of positron emission tomography in urological oncology. BJU Int 2010, 106:1578-1593.